Akari Therapeutics PLC (NASDAQ:AKTX) Stock Has Consensus Target Price of $32.33

Shares of Akari Therapeutics PLC (NASDAQ:AKTX) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $32.33.

Several equities research analysts have issued reports on AKTX shares. Alliance Global Partners upgraded Akari Therapeutics to a “strong-buy” rating in a research report on Friday, September 18th. Maxim Group upgraded Akari Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a research report on Monday, July 20th. Wall Street Zen upgraded Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Akari Therapeutics in a report on Friday, October 2nd.

Akari Therapeutics Stock Down 6.9%

AKTX opened at $7.13 on Wednesday. Akari Therapeutics has a 12 month low of $3.02 and a 12 month high of $29.32. The company has a 50 day moving average of $9.15 and a 200 day moving average of $9.01.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The company’s research centers on complement-system and leukotriene biology, which are involved in immune responses and inflammation. Its lead investigational product is nomacopan, a recombinant protein designed to inhibit complement component C5 and leukotriene B4. Akari is also developing PAS-nomacopan, a longer-acting version intended to extend the therapy’s duration of action.